High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa
Eur J Dermatol
.
2019 Dec 1;29(6):659-661.
doi: 10.1684/ejd.2019.3663.
Authors
Lisa Scholl
1
,
Schapoor Hessam
2
,
Simone Garcovich
3
,
Falk G Bechara
1
Affiliations
1
Dermatologic Surgery Unit, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany.
2
Department of Dermatology, Katharinen Hospital, Unna, Germany.
3
Institute of Dermatology, F. Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
PMID:
31903963
DOI:
10.1684/ejd.2019.3663
No abstract available
Publication types
Case Reports
Letter
MeSH terms
Adult
Dermatologic Agents / administration & dosage*
Female
Hidradenitis Suppurativa / drug therapy*
Humans
Male
Severity of Illness Index
Ustekinumab / adverse effects*
Substances
Dermatologic Agents
Ustekinumab